Phase 1 Clinical Trial of Losmapimod in Facioscapulohumeral Dystrophy (FSHD): Safety, Tolerability, Pharmacokinetics, and Target Engagement

2021 ◽  
Author(s):  
Michelle L. Mellion ◽  
Lucienne Ronco ◽  
Cecile L. Berends ◽  
Lisa Pagan ◽  
Sander Brooks ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase 1 ◽  
Target Engagement ◽  
Facioscapulohumeral Dystrophy ◽  
Phase 1 Clinical Trial

scholarly journals Safety and immunogenicity of a quadrivalent inactivated subunit non-adjuvanted influenza vaccine: A randomized, double-blind, active-controlled phase 1 clinical trial

Vaccine ◽  
2021 ◽  
Author(s):  
Yanxia Wang ◽  
Yuhui Zhang ◽  
Haofei Wu ◽  
Lili Huang ◽  
Hailong Yu ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Influenza Vaccine ◽  
Phase 1 ◽  
Double Blind ◽  
Phase 1 Clinical Trial

A Phase 1 clinical trial of Hantaan virus and Puumala virus M-segment DNA vaccines for hemorrhagic fever with renal syndrome

Vaccine ◽  
2012 ◽  
Vol 30 (11) ◽  
pp. 1951-1958 ◽  
Author(s):  
Ellen F. Boudreau ◽  
Matthew Josleyn ◽  
Diane Ullman ◽  
Diana Fisher ◽  
Lonnie Dalrymple ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Dna Vaccines ◽  
Phase 1 ◽  
Hemorrhagic Fever ◽  
Hantaan Virus ◽  
Puumala Virus ◽  
Phase 1 Clinical Trial

1238 POSTER Phase 1 Clinical Trial of Oral PPAR – Agonist Efatutazone (CS-7017) in Japanese Patients With Metastatic Solid Tumours

2011 ◽  
Vol 47 ◽  
pp. S156
Author(s):  
N. Yamamoto ◽  
H. Murakami ◽  
Y. Onozawa ◽  
T. Ono ◽  
T. Tushima ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Phase 1 ◽  
Japanese Patients ◽  
Solid Tumours ◽  
Phase 1 Clinical Trial ◽  
Ppar Agonist

scholarly journals A phase 1 clinical trial of long-term, low-dose treatment of WHIM syndrome with the CXCR4 antagonist plerixafor

Blood ◽  
2014 ◽  
Vol 123 (15) ◽  
pp. 2308-2316 ◽  
Author(s):  
David H. McDermott ◽  
Qian Liu ◽  
Daniel Velez ◽  
Lizbeeth Lopez ◽  
Sandra Anaya-O’Brien ◽  
...  
Keyword(s):  
Clinical Trial ◽  
Low Dose ◽  
Phase 1 ◽  
Cxcr4 Antagonist ◽  
Phase 1 Clinical Trial ◽  
Dose Treatment ◽  
Whim Syndrome ◽  
Key Points

Key Points Plerixafor can be given safely to WHIM syndrome patients twice daily for a 6-month period and appears promising as a treatment.

scholarly journals Phase 1 clinical trial: Growing role of anesthetists in India

2010 ◽  
Vol 56 (4) ◽  
pp. 333
Author(s):  
RK Ghosh ◽  
SM Ghosh
Keyword(s):  
Clinical Trial ◽  
Phase 1 ◽  
Phase 1 Clinical Trial
Sign in / Sign up

Export Citation Format

Share Document